|View printer-friendly version|
|Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2005|
BOULDER, Colo., Feb. 7 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY) today reported financial results for the second quarter of fiscal 2005, ended December 31, 2004.
For the second quarter of fiscal 2005, Array reported total revenue of $12.0 million, compared to revenue of $7.6 million for the same period in fiscal 2004. Revenue increased from recognizing $1.8 million in additional up-front and milestone payments and $2.6 million in research funding from additional collaborations and research tools sales. Net loss was $4.9 million, or ($0.16) per share, for the second quarter, compared to a net loss of $6.3 million, or ($0.22) per share, for the same quarter in fiscal 2004. Array ended the second quarter of fiscal 2005 with $96.9 million in cash and marketable securities.
"Array has secured the financial resources to accelerate and broaden our product pipeline focused primarily on treatments for cancer and inflammatory disease," said Robert E. Conway, Chief Executive Officer, Array BioPharma. "With nearly $100 million in available funds, we will increase our investment in proprietary research and plan to advance additional programs into clinical development over the next two years."
Second Quarter of Fiscal 2005 Accomplishments:
Strengthening Financial Position
Advancing Proprietary Research Programs
Expanding Research Collaborations
Array reported revenue of $21.9 million for the six-month period ended December 31, 2004, compared to revenue of $14.8 million for the same period in fiscal 2004. Net loss for the six months ended December 31, 2004, was $10.5 million, or ($0.35) per share, compared to a net loss of $12.2 million, or ($0.43) per share, reported in the same period in fiscal 2004.
Array will hold a conference call on Tuesday, February 8, 2005, at 9:00 a.m. eastern time to discuss these results. If there is any additional information provided during this call, it will be available on a replay of the call and as a web cast on www.arraybiopharma.com. Robert E. Conway, Chief Executive Officer, and Michael Carruthers, Chief Financial Officer, will lead the call.
Conference Call Information
There will be a replay of the conference call for one week, which can be accessed in the United States by dialing toll-free (888) 203-1112, and outside the United States (719) 457-0820. The access code is 4641732. A replay of the call will also be available as a web cast on Array's web site at www.arraybiopharma.com.
About Array BioPharma:
Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of orally active drugs to address significant unmet medical needs. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. In addition, leading pharmaceutical and biotechnology companies access our drug discovery technologies and expertise through collaborations to design, create, optimize and evaluate drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2004, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties for their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet drug objectives, including clinical trials, tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of February 7, 2005. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
Array BioPharma Inc. Condensed Statement of Operations (in thousands, except per share amounts) Three Months Ended Six Months Ended December 31, December 31, 2004 2003 2004 2003 (unaudited) (unaudited) Revenue: Collaboration revenue $9,548 $6,907 $16,893 $13,918 License and milestone revenue 2,500 688 5,012 872 Total revenue 12,048 7,595 21,905 14,790 Operating expenses: Cost of revenue including related research and development 9,464 7,230 18,257 14,482 Research and development for proprietary drug discovery 5,312 4,565 9,794 8,597 Selling, general and administrative 2,341 2,138 4,676 4,078 Total operating expenses 17,117 13,933 32,727 27,157 Loss from operations (5,069) (6,338) (10,822) (12,367) Interest income 192 77 330 169 Net loss $(4,877) $(6,261) $(10,492) $(12,198) Basic and diluted net loss per share $(0.16) $(0.22) $(0.35) $(0.43) Number of shares used to compute per share data 30,706 28,388 29,807 28,324 Summary Balance Sheet Data (in thousands) December 31, June 30, 2004 2004 (unaudited) Cash, cash equivalents and marketable securities $96,928 $37,446 Property, plant and equipment, gross 60,138 57,557 Working capital 81,656 25,905 Total assets 135,564 77,764 Stockholders' equity 112,812 55,630